Literature DB >> 21800378

Structural and conformational features relevant to the anti-tumor activity of calicheamicin γ 1I.

George A Ellestad1.   

Abstract

The structural and conformational features of the potent 10-membered enediyne-containing calicheamicin γ 1I that account for its remarkable DNA site-specific binding and cleavage are reviewed. A variety of spectroscopic and biophysical techniques were used to gain insight into the binding and stereospecific DNA cleavage of this potent antitumor agent. These include gel-shift cleavage assays, atom transfer NMR experiments, drug-DNA conformational studies, circular dichroism, and capillary electrophoresis. Computational descriptions are described for the DNA binding and cleavage of calicheamicin and its activated transient intermediates based on density functional and molecular mechanics calculations. In addition, the structure and clinical utility of calicheamicin immunoconjugates for antibody-targeted chemotherapy is presented.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21800378     DOI: 10.1002/chir.20990

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  5 in total

1.  Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia.

Authors:  Michael Rytting; Lisa Triche; Deborah Thomas; Susan O'Brien; Hagop Kantarjian
Journal:  Pediatr Blood Cancer       Date:  2013-09-02       Impact factor: 3.167

2.  A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).

Authors:  Erica Brivio; Franco Locatelli; Marta Lopez-Yurda; Andrea Malone; Cristina Díaz-de-Heredia; Bella Bielorai; Claudia Rossig; Vincent H J van der Velden; Anneke C J Ammerlaan; Adriana Thano; Inge M van der Sluis; Monique L den Boer; Ying Chen; Barbara Sleight; Benoit Brethon; Karsten Nysom; Lucie Sramkova; Ingrid Øra; Luciana Vinti; Christiane Chen-Santel; Christian Michel Zwaan
Journal:  Blood       Date:  2021-03-25       Impact factor: 22.113

3.  Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.

Authors:  Mohammed Gbadamosi; Soheil Meshinchi; Jatinder K Lamba
Journal:  Future Oncol       Date:  2018-07-24       Impact factor: 3.404

Review 4.  Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics.

Authors:  Eunhee G Kim; Kristine M Kim
Journal:  Biomol Ther (Seoul)       Date:  2015-11-01       Impact factor: 4.634

Review 5.  Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products.

Authors:  Matthew Trendowski
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.